Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors

Ted Kamenecka, Rong Jiang, Xinyi Song, Derek Duckett, Weimin Chen, Yuan Yuan Ling, Jeff Habel, John D. Laughlin, Jeremy Chambers, Mariana Figuera-Losada, Michael D. Cameron, Li Lin, Claudia H. Ruiz, Philip V. LoGrasso

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Given the significant body of data supporting an essential role for c-jun-N-terminal kinase (JNK) in neurodegenerative disorders, we set out to develop highly selective JNK inhibitors with good cell potency and good brain penetration properties. The structure-activity relationships (SAR) around a series of aminopyrimidines were evaluated utilizing biochemical and cell-based assays to measure JNK inhibition and brain penetration in mice. Microsomal stability in three species, P450 inhibition, inhibition of generation of reactive oxygen species (ROS), and pharmacokinetics in rats were also measured. Compounds 9g, 9i, 9j, and 9l had greater than 135-fold selectivity over p38, and cell-based IC50 values < 100 nM. Moreover, compound 9l showed an IC50 = 0.8 nM for inhibition of ROS and had good pharmacokinetic properties in rats along with a brain-to-plasma ratio of 0.75. These results suggest that biaryl substituted aminopyrimidines represented by compound 9l may serve as the first small molecule inhibitors to test efficacy of JNK inhibitors in neurodegenerative disorders.

Original languageEnglish (US)
Pages (from-to)419-431
Number of pages13
JournalJournal of Medicinal Chemistry
Volume53
Issue number1
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

JNK Mitogen-Activated Protein Kinases
Pharmacokinetics
X-Rays
Neurodegenerative Diseases
Inhibitory Concentration 50
Reactive Oxygen Species
Brain
Structure-Activity Relationship
2-aminopyrimidine

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors. / Kamenecka, Ted; Jiang, Rong; Song, Xinyi; Duckett, Derek; Chen, Weimin; Ling, Yuan Yuan; Habel, Jeff; Laughlin, John D.; Chambers, Jeremy; Figuera-Losada, Mariana; Cameron, Michael D.; Lin, Li; Ruiz, Claudia H.; LoGrasso, Philip V.

In: Journal of Medicinal Chemistry, Vol. 53, No. 1, 2010, p. 419-431.

Research output: Contribution to journalArticle

Kamenecka, T, Jiang, R, Song, X, Duckett, D, Chen, W, Ling, YY, Habel, J, Laughlin, JD, Chambers, J, Figuera-Losada, M, Cameron, MD, Lin, L, Ruiz, CH & LoGrasso, PV 2010, 'Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors', Journal of Medicinal Chemistry, vol. 53, no. 1, pp. 419-431. https://doi.org/10.1021/jm901351f
Kamenecka, Ted ; Jiang, Rong ; Song, Xinyi ; Duckett, Derek ; Chen, Weimin ; Ling, Yuan Yuan ; Habel, Jeff ; Laughlin, John D. ; Chambers, Jeremy ; Figuera-Losada, Mariana ; Cameron, Michael D. ; Lin, Li ; Ruiz, Claudia H. ; LoGrasso, Philip V. / Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors. In: Journal of Medicinal Chemistry. 2010 ; Vol. 53, No. 1. pp. 419-431.
@article{6a54e2f2c2804732bd0e874d8fc74575,
title = "Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors",
abstract = "Given the significant body of data supporting an essential role for c-jun-N-terminal kinase (JNK) in neurodegenerative disorders, we set out to develop highly selective JNK inhibitors with good cell potency and good brain penetration properties. The structure-activity relationships (SAR) around a series of aminopyrimidines were evaluated utilizing biochemical and cell-based assays to measure JNK inhibition and brain penetration in mice. Microsomal stability in three species, P450 inhibition, inhibition of generation of reactive oxygen species (ROS), and pharmacokinetics in rats were also measured. Compounds 9g, 9i, 9j, and 9l had greater than 135-fold selectivity over p38, and cell-based IC50 values < 100 nM. Moreover, compound 9l showed an IC50 = 0.8 nM for inhibition of ROS and had good pharmacokinetic properties in rats along with a brain-to-plasma ratio of 0.75. These results suggest that biaryl substituted aminopyrimidines represented by compound 9l may serve as the first small molecule inhibitors to test efficacy of JNK inhibitors in neurodegenerative disorders.",
author = "Ted Kamenecka and Rong Jiang and Xinyi Song and Derek Duckett and Weimin Chen and Ling, {Yuan Yuan} and Jeff Habel and Laughlin, {John D.} and Jeremy Chambers and Mariana Figuera-Losada and Cameron, {Michael D.} and Li Lin and Ruiz, {Claudia H.} and LoGrasso, {Philip V.}",
year = "2010",
doi = "10.1021/jm901351f",
language = "English (US)",
volume = "53",
pages = "419--431",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors

AU - Kamenecka, Ted

AU - Jiang, Rong

AU - Song, Xinyi

AU - Duckett, Derek

AU - Chen, Weimin

AU - Ling, Yuan Yuan

AU - Habel, Jeff

AU - Laughlin, John D.

AU - Chambers, Jeremy

AU - Figuera-Losada, Mariana

AU - Cameron, Michael D.

AU - Lin, Li

AU - Ruiz, Claudia H.

AU - LoGrasso, Philip V.

PY - 2010

Y1 - 2010

N2 - Given the significant body of data supporting an essential role for c-jun-N-terminal kinase (JNK) in neurodegenerative disorders, we set out to develop highly selective JNK inhibitors with good cell potency and good brain penetration properties. The structure-activity relationships (SAR) around a series of aminopyrimidines were evaluated utilizing biochemical and cell-based assays to measure JNK inhibition and brain penetration in mice. Microsomal stability in three species, P450 inhibition, inhibition of generation of reactive oxygen species (ROS), and pharmacokinetics in rats were also measured. Compounds 9g, 9i, 9j, and 9l had greater than 135-fold selectivity over p38, and cell-based IC50 values < 100 nM. Moreover, compound 9l showed an IC50 = 0.8 nM for inhibition of ROS and had good pharmacokinetic properties in rats along with a brain-to-plasma ratio of 0.75. These results suggest that biaryl substituted aminopyrimidines represented by compound 9l may serve as the first small molecule inhibitors to test efficacy of JNK inhibitors in neurodegenerative disorders.

AB - Given the significant body of data supporting an essential role for c-jun-N-terminal kinase (JNK) in neurodegenerative disorders, we set out to develop highly selective JNK inhibitors with good cell potency and good brain penetration properties. The structure-activity relationships (SAR) around a series of aminopyrimidines were evaluated utilizing biochemical and cell-based assays to measure JNK inhibition and brain penetration in mice. Microsomal stability in three species, P450 inhibition, inhibition of generation of reactive oxygen species (ROS), and pharmacokinetics in rats were also measured. Compounds 9g, 9i, 9j, and 9l had greater than 135-fold selectivity over p38, and cell-based IC50 values < 100 nM. Moreover, compound 9l showed an IC50 = 0.8 nM for inhibition of ROS and had good pharmacokinetic properties in rats along with a brain-to-plasma ratio of 0.75. These results suggest that biaryl substituted aminopyrimidines represented by compound 9l may serve as the first small molecule inhibitors to test efficacy of JNK inhibitors in neurodegenerative disorders.

UR - http://www.scopus.com/inward/record.url?scp=74849136062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74849136062&partnerID=8YFLogxK

U2 - 10.1021/jm901351f

DO - 10.1021/jm901351f

M3 - Article

C2 - 19947601

AN - SCOPUS:74849136062

VL - 53

SP - 419

EP - 431

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 1

ER -